Related Experiment Videos

Suppression of tumor growth and pulmonary metastasis in murine osteosarcoma using gene therapy

Masashi Seto1, Takashi Yamazaki, Jun Sonoda

  • 1Department of Orthopaedic Surgery, Mie University School of Medicine, Tsu city, Mie prefecture 514, Japan. m-seto@clin.medic.mie-u.ac.jp

Oncology Reports
|February 12, 2002
PubMed

Insights

Gene therapy using herpes simplex virus thymidine kinase (HSV-tk) and ganciclovir (GCV) effectively inhibited osteosarcoma tumor growth and lung metastasis in mice. This approach demonstrated significant anti-tumor activity in both cell cultures and living organisms.

Area of Science:

  • Oncology
  • Gene Therapy
  • Cancer Metastasis

Background:

  • Osteosarcoma is a primary bone cancer with a high propensity for lung metastasis.
  • Gene therapy offers a potential strategy to target cancer cells and inhibit metastasis.

Purpose of the Study:

  • To evaluate the efficacy of gene therapy using herpes simplex virus thymidine kinase (HSV-tk) in combination with ganciclovir (GCV) against murine osteosarcoma.
  • To assess the impact of this gene therapy on tumor growth and pulmonary metastasis in vivo.

Main Methods:

  • Murine osteosarcoma LM8 cells were transduced with the HSV-tk gene or Escherichia coli beta-galactosidase (lacZ) gene.
  • Cytotoxicity of HSV-tk transduced cells was assessed after treatment with ganciclovir (GCV) in vitro.
  • Tumor growth and lung metastasis inhibition were evaluated in vivo.

Main Results:

  • LM8 cells engineered to express HSV-tk exhibited increased sensitivity to ganciclovir (GCV) compared to control cells.
  • Significant inhibition of primary tumor growth was observed in vivo.
  • A remarkable reduction in pulmonary metastases was confirmed in treated mice.

Conclusions:

  • Gene therapy with HSV-tk and subsequent ganciclovir treatment is a potent strategy for controlling osteosarcoma.
  • This approach effectively reduces both primary tumor burden and metastatic spread to the lungs.

Related Concept Videos